Search results “Annual sales of nexium”
Acid Reflux, GERD, Heartburn. The cause and solution by Dr. Peter Glidden
Acid reflux also known as heartburn or GERD (Gastroesophageal Reflux Disease) plagues 20% of the population unnecessarily. Yes that’s correct unnecessarily! So why are Proton Pump inhibitors (PPIs) drugs like Nexium, Prilosec, and Prevacid among the highest-selling classes of drugs in North America? To the tune of 9.5 billion in annual sales. Because medical doctors have it wrong when it concerns Acid Reflux. They do not know what causes it and they don't know how to cure it. So they make Billions managing it... Here are eight risk factors that Do Not cause heartburn: Smoking Pregnancy Eating a large meals Eating just before bed Lying down right after a meal Drinking alcohol, tea or coffee Eating spicy foods, citrus, fatty foods, chocolate, onions or garlic Taking medication such as aspirin, muscle relaxers or blood pressure medication These factors are known to trigger heartburn. But remember correlation does not equal causation. Medical doctors have told you that acid reflux is a result of too much stomach acid - but they can't tell you why or how this happens (it doesn't). Their ad hoc solution is to give a PPI to stop the production of stomach acid….The result no more GERD. This is like cutting off a finger to eliminate finger pain. It is an out of date, juvenile prescription which completely misses the point. Par for the course in MD land. The reality of the situation us that Acid Reflux is caused by not enough stomach acid! More about Dr. Glidden Take the supplements that Dr. Glidden takes! http://www.eiffelhealth.com 1.888.618.1796 Click here to subscribe to our YouTube Channel! https://www.youtube.com/channel/UClsv...... Checkout the podcast! http://www.glidden.healthcare/podcast/ Checkout our recent vodcasts! http://www.glidden.healthcare/vodcast/ EDUCATION • 1976 – 1977: Williams College, Williamstown MA • 1980: Certified to teach Yoga by the state of California after completing a 6 month intensive Yoga Teacher Training course at Ananda Cooperative Community in Grass Valley, CA • 1987: BS Pre Med – University of Massachusetts, Amherst MA • 1991: Doctoral Degree in Naturopathic Medicine (ND) – Bastyr University, Seattle WA • 1987 – Present: Member of American Association of Naturopathic Physicians • 1992 – 2002: Member Massachusetts Society of Naturopathic Physicians • 1992 – Present: Private practice of Naturopathic Medicine HAS BEEN LICENSED TO PRACTICE NATUROPATHIC MEDICINE SINCE 1992 • Over 150 lectures worldwide since 2009 • Author of "The MD Emperor Has No Clothes • Radio host of "The Dr. Glidden Show" 1 hour weekday program on GCNLive.com • Regular guest on Radio show "Dead Doctor's Don't Lie" since 2010 • Television appearances on public TV promoting Naturopathic Medicine. More from Dr. Glidden www.glidden.healthcare.com on Twitter @ drpeterglidden on Instagram https://instagram.com/gliddenhealthcare
Views: 13321 Glidden Healthcare
Top 10 pharmaceutical companies
Who are the top 10 pharmaceutical companies in the world? Watch this video and know the best and the biggest top 10 pharmaceutical companies in the world. 10. Gilead Sciences Revenue: $24.474 billion The US biopharmaceutical organization, best known for creating antivirals, additionally has a strong business arrangement of life-sparing medications in cardiovascular and respiratory treatments. Gilead secures its entrance into the main ten rundown over a few major pharma names as a result of mind blowing late development energized by its fresh out of the plastic new blockbuster hepatitis C drug, Sovaldi. Gilead's business sector driving pharmaceuticals incorporate medications for HIV/AIDS, growth, liver malady and cardiovascular ailment. 9. Bayer Revenue: $25.47 billion The Leverkusen-based medication creator has a great business arrangement of more than 5000 items. Notwithstanding human and veterinary pharmaceuticals, they additionally work in purchaser medicinal services and rural chemicals. Bayer's main five medications incorporate anticoagulant Xarelto, eye pharmaceutical Eylea, malignancy drugs Stivarga and Xofigo, and pneumonic blood vessel hypertension drug Adempas. 8. AstraZeneca Revenue: $26.095 billion AstraZeneca has an arrangement of items for real ailments, including malignancy, cardiovascular malady, gastrointestinal contamination, neurological scatters, respiratory sickness and irritation. Current top-offering items incorporate cholestorol treatment Crestor, asthma treatment Symbicort and indigestion pill Nexium, and the UK-based pharmaceutical organization is likewise said to have a solid pipeline of oncology treatments. AstraZeneca effectively fought off takeover offers from Pfizer in 2014 and has layed-out eager focuses for future development, which if fruitful could see it enhance its rank among the main ten rundown of pharmaceutical organizations. 7. GlaxoSmithKline Revenue: $37.96 billion GSK builds up a wide scope of items in pharmaceuticals, antibodies and buyer medicinal services, and has driving items crosswise over different restorative zones including cardiovascular and respiratory illness, asthma, disease, contaminations, psychological wellness, diabetes and digestive conditions. GSK had great development in developing markets, Japan, and the organization's HIV division a year ago, however its general gathering turnover fell beneath their 2013 figures making them drop down the rankings. In April, Glaxo concurred more than $20 billion in manages Novartis, offering its oncology business to and purchasing the main part of Novartis' immunization unit, making them the biggest antibodies organization all inclusive. GSK connected for administrative endorsement in 2014 for the primary intestinal sickness antibody and right now has one of the main possibility for an Ebola immunization experiencing clinical trials. 6. Merck Revenue: $42.237 billion Merck conveyed to showcase their exceptionally encouraging tumor treatment Keytruda in 2014, one of six medications that got FDA endorsement around the same time, including endorsements for sleep deprivation treatment Belsomra and Zerbaxa, the Cubist item affirmed to treat doctor's facility procured diseases. As of August 2014, Merck's innovative work exertion has prompted the endorsement of more new medications than some other organization. Their master helpful ranges incorporate oncology, neurodegenerative maladies, richness and endocrinology. Merck is likewise surely understood for distributed The Merck Manuals, a progression of smash hit restorative reference books for doctors, medical attendants and experts. 5. Sanofi Revenue: $43.07 billion French pharmaceutical organization Sanofi works in solution and over the counter (OTC) prescriptions in seven noteworthy remedial territories: cardiovascular, focal sensory system, diabetes, inner drug, oncology, thrombosis and antibodies. Diabetes blockbuster Lantus remains the wellspring of a great part of the organization's turnover, bolstered by antibodies and numerous sclerosis treatments at its biotech unit Genzyme, and antihistamine Allegra in Sanofi's purchaser wellbeing division. Toward the start of February 2015, the Sanofi's R&D pipeline contained 43 ventures (barring Life Cycle Management) and immunization applicants in clinical advancement of which 14 are in stage 3 or have been submitted to the administrative powers for endorsement. Thanks for watching this video. for more info kindly visit our website www.manishweb.com
Views: 12387 Manish Verma
DANGEROUS TRUTH WITH MY PERSONAL STORY AND FACTS ABOUT XARELTO ALSO CALLED RIVAROXABAN (BLOOD THINNER) AND NSAIDS SUCH AS NAPROXEN, ALEVE, IBUPROFEN, MOTRIN, ADVIL "No Antidote While all blood thinners carry the risk of internal bleeding, older drugs like warfarin have emergency antidotes to prevent serious harm. Xarelto does not have an antidote, and the drug cannot be flushed out of the system through dialysis. People who suffer bleeding can end up hospitalized, and the bleed may be fatal." Erin Brokovich info and taking claims for XARELTO http://www.brockovich.com/portfolio/xarelto/ Papantonio: Big Pharma Gone Wild – The Xarelto Scam http://www.youtube.com/watch?v=r6MD3wQaGFw New Research Confirms that NSAIDs Can Be Deadly http://www.peoplespharmacy.com/2014/09/29/new-research-confirms-that-nsaids-can-be-deadly/ Common painkillers can cause blood clots http://sciencenordic.com/common-painkillers-can-cause-blood-clots What is the Best and Safest Anti-Coagulation Therapy? Here are the facts, you decide... http://www.advancedcardioservices.com/blog/what-is-the-best-and-safest-anti-coagulation-therapy-here-are-the-facts-you-decide.html HOW TO FIND OUT IF COMPANY IS TRULY CRUELTY FREE - TIPS, EXPERIENCES AND CALL TO ACTION WHAT WE CAN ALL DO!!!! http://www.youtube.com/watch?v=q4Itld... Websites and many tips on how to find out if company is TRULY cruelty free, cutting through the lies, and tips on on contacting companies to ask yourselves. REMINDER - if there is a pink/purple square beside name that means owned by company who tests on animals and money goes to company who tests, you decide on that, but to me i see it as paying for animal testing.http://leapingbunny.org/shopping.php Leaping Bunny Info. and FAQ's http://www.youtube.com/watch?v=1KVOBD... PETA companies who DO TEST on animals (reminder, the do not test list is NOT RELIABLE up to date in my and many other opinions and therefore would not recommend it).http://www.peta.org/living/beauty-and... Veggiebeauty form letter to ask companies if they test or not (maker of pumpkin & poppy cosmetics)http://veggiebeauty.com/form-letter To Whomever it May Concern:I am doing research on animal testing, and I need to verify a few key points about your company. 1. Does your company test ingredients or finished products on animals?2. Do you test ingredients or products on animals through a 3rd party?3. Do your manufacturers test ingredients or products on animals? 4. Are you owned or affiliated with any companies that test products or ingredients on animals?5. Do you/your parent company currently or have plans to market and sell your products in the Chinese market, which requires animal testing by law to sell in that country?Thank you so much for the information. IF YOU WISH TO ASK VEGAN QUESTION:7. Could you provide a list of all of your current vegan items available for purchase? ASKING COMPANIES TO JOIN LEAPING BUNNY SAMPLE LETTER (please edit to what feels right for you!) Hello, I am writing to you because it is my understanding from previous emails with you, that you and your manufactures or truly do not test on animals, no 3rd party teasing or sell in China where it is required by law. I am also glad you are not owned or affiliated by any company that tests on animals, THANK YOU! Many people on youtube channels, blogs, and elsewhere on the internet,have been asking that more companies go beyond saying they are cruelty free and prove it by jointing the leaping bunny standard as many companies around the world have done, such as famous brand FACE ATELIER. The Logo is also the only international icon that represents the most stringent non-animal testing standard. I do feel that if you do join, not only is this an ethical choice, but from a marketing perspective, will increase your sales dramatically as leaping bunny is the most respected cruelty free standard in the world. After you have completed the forms, it only takes about a week to be officially certified, be sure to follow up :) How much does it cost a company to join? There are no costs associated with joining the Leaping Bunny Program. However, companies that choose to license the Leaping Bunny Logo must pay a one-time fee, which operates on a sliding scale, based on a company's gross annual sales. IS THIS SOMETHING YOU ARE WILLING TO DO? THE BEST PART IS, IT'S FREE!
Views: 11880 **SeeYourStar**
More selling drugs in America
Finished drug "Crestor" the first rank in the hierarchy of the annual sales of the drug in the US market, and is considered "Crestor" which is the trade name for the drug is named scientifically as "Roseovastaten" of antihypertensive medications for cholesterol. According to statistical study carried out by the company "IMS" Health in the United States of America; the value of prescription drugs sold over the past year to US $ 23.7 million.
Views: 28 kate lendor
Big Pharma 'Drug Pushers' to the Public
Big Pharma , 'Drug Pushers' to the Public. One thing is very obvious today. big pharmaceutical and modern medicine is almost exclusively about profit. Each year big pharmaceutical and modern medicine sets new goals to increase revenues from pharmaceutical drug sales. Often it's the public that is used or new profit driven pharmaceutical drugs with heavy media advertising directed at the public to push pharma drug sales higher of new and often not well tested pharmaceutical drugs. A very strong word on 'alternative' medicine. Since the public is now becoming strongly suspicious of big pharmaceutical medicine there is now a growing booming business in 'alternative' medicine. But not all 'alternative' medicine lives up to their claims either. But I would like to state one well documented virtual 'cure-all' that is ignored by the medical establishment that was proven by some doctors repeatedly over many years. Such medical doctors would include William F. Klenner, Thomas Levy. Reardon, Cathcart and also the 2 time Nobel Peace Prize winner Linus Pauling. The virtual 'cure all' is massive doses of vitamin C administered directly into the blood by IV. Vitamin C is actually a powerful and very safe hormone that is not only an absolute virucide, but will also neutralize toxins and radiation while greatly assisting the body to repair tissue damage and heal. The problem of vitamin C (hormone C) is that it's very inexpensive and can't be patented so the pharmaceutical drug industry will never realize a substantial profit from sales of vitamin C. Vitamin C in the right form and administered by the right method can replace most of the pharmaceuticals being sold on the medical market today. Bottom line is that patented medicines are where the profits are generated and patented medicines are very much akin to having a monopoly business model. There is one very effective method whereby oral vitamin C can work against many ailments. The product Livon Labs Liposomal Vitamin C was thoroughly tested by Dr Thomas Levy on many patients and used in addressing many severe medical ailments. Livon Labs Liposomal Vitamin C in higher doses, combined with 'bowel tolerance' plain oral vitamin C has been found to be at least as effective and often more effective that high dosage intravenous vitamin C. So there is another very effective method that anyone could take enough vitamin C orally and have the vitamin C reach the areas of the body where it's most needed.
Views: 587 syyenergy7
ESSO 06-20-14
ESSO 06-20-14
Views: 35 ESSO Santa Fe
"Toller Arbeitgeber 2017": AstraZeneca
AstraZeneca, Wedel
Views: 1365 WiMi SH
AstraZeneca and Plan
One of the world's leading pharmaceutical companies, AstraZeneca, has chosen Plan as the main NGO delivery partner for its ground-breaking Young Health Programme (YHP). The programme is designed to help disconnected young people around the world understand and deal with the health issues they face. Plan's UK chief executive Marie Staunton said: "AstraZeneca's support to Plan will initially give more than 70,000 adolescents in Brazil and India a healthier future through being given the right information, knowledge and tools to help them make better health choices and advocate for better health services now and in the future."
Views: 518 Plan International
Seclo® MUPS

20mg Tablets - Square Pharmaceutical Ltd.
More Information - http://www.squarepharma.com.bd/products-details.php?pid=678
Views: 1161 Point Lab
India - AstraZeneca India
A customer testimonial showing how the Buchi rotary evaporators or rotavapors are used in their labs and what applications are useful for the pharmaceutical industry
Views: 505 BuchiCorp
Telecom Review Summit 2013: Wholesale: Voice or Data
Wholesale: Voice or Data • The death of voice or beginning of new opportunities? • The new opportunities in wholesale market • Adjusting to market's difficult conditions • Roaming issues and challenges Moderator: Jeff Seal, Managing Partner, Telecom Review, North America Panelists: Ali Al Amiri, Executive Vice President, Carrier and Wholesale Services, Etisalat - Khaled Tabbara, Wholesale Division, du - Karim El-Khazen, VP, Business Development and Innovation, Deutsche Telekom - Margot Moussy, Head of Sales, TeliaSonera, MEA & Africa - Imran Hussain, Regional director, BT, Middle East & North Africa - Tony Kelly, Group Sales Director, Verizon Global Wholesale
Views: 143 TelecomReviewTV
Global Peptic Ulcer Drugs Market 2015 Size, Share, Forecast 2018
Global Peptic Ulcer Drugs Market 2014-2018 http://www.marketresearchstore.com/report/global-peptic-ulcer-drugs-market-2014-2018-10800 About Peptic Ulcer and Drugs Used for the Treatment A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. Table of Content 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market Overview 03.2 Product Offerings 04. Product Profiles 04.1.1 Nexium 04.1.2 Losec 04.1.3 Vimovo 04.1.4 Pariet 04.1.5 Selbex 04.1.6 Albis 04.1.7 Lanpra/ Prevacid 04.1.8 Dexilant 04.1.9 Takelda 05. Market Research Methodology 05.1 Market Research Process 05.2 Research Methodology 06. Introduction 07. Market Landscape 07.1 Market Overview 07.2 Market Size and Forecast 07.3 Five Forces Analysis 08. Pipeline Portfolio 08.1 Key Information for the Pipeline Candidates 08.1.1 PA32540 08.1.2 TAK-438 08.1.3 Lafutidine 08.1.4 D961H 08.1.5 PMK-S005 08.1.6 YF476 09. Market Segmentation by Class of Drugs 09.1 Proton Pump Inhibitors 09.2 H2 Receptor Antagonists 09.3 Gastric Mucosal Protective Drugs 09.4 Antacids 09.5 Antibiotics 09.6 Prostaglandin Agonists 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 18.1 Competitive Scenario 18.1.1 Key News 18.1.2 Mergers and Acquisitions 18.2 Market Share Analysis 2013 18.3 Other Prominent Vendors & Expected Future Vendors 19. Key Vendor Analysis 19.1 AstraZeneca plc 19.1.1 Key Facts 19.1.2 Business Description 19.1.3 Business Segmentation 19.1.4 Business Strategy 19.1.5 Revenue by Business Segmentation 19.1.6 Revenue Comparison 2011-2013 19.1.7 Sales Revenue by Geographical Segmentation 19.1.8 Key Developments 19.1.9 SWOT Analysis 19.1.10 Strengths 19.1.11 Weaknesses 19.1.12 Opportunities 19.1.13 Threats 19.2 Daewoong Pharmaceutical 19.2.1 Key Facts 19.2.2 Business Overview 19.2.3 Business Segmentation by Revenue 2013 19.2.4 Business Segmentation by Revenue 2012 and 2013 19.2.5 Geographical Segmentation by Revenue 2013 19.2.6 Business Strategy 19.2.7 Recent Developments 19.2.8 SWOT Analysis 19.2.9 Strengths 19.2.10 Weaknesses 19.2.11 Opportunities 19.2.12 Threats 19.3 Eisai Co 19.3.1 Key Facts 19.3.2 Business Overview 19.3.3 Comparison between Revenue, Operating Income, and Net Income 19.3.4 Sales by Geography 19.3.5 Business Strategy 19.3.6 Key Information 19.3.7 SWOT Analysis 19.3.8 Strengths 19.3.9 Weaknesses 19.3.10 Opportunities 19.3.11 Threats 19.4 Takeda Pharmaceuticals 19.4.1 Key Facts 19.4.2 Business Overview 19.4.3 Business Segmentation by Revenue 2013 19.4.4 Business Segmentation by Revenue 2013 19.4.5 Geographical Segmentation by Revenue 2013 19.4.6 Business Strategy 19.4.7 Recent Developments 19.4.8 SWOT Analysis 19.4.9 Strengths 19.4.10 Weakness 19.4.11 Opportunities 19.4.12 Threats
Catagory Management Conference Highlights
Atlanta Business Video is available for live events- check out the highlight reel from the 2008 Category Management Conference in Atlanta, GA! For more information, please visit http://www.atlantabusinessvideo.com!
Brilinta acc 2014
via YouTube Capture
Fake Esso capsule by shaigan pharma
Fake cap esso by shaigan pharma
Views: 693 Hacking Updates
Sales Meeting Introduction SPACE
New animation for IDS, space the final frontier in the data world
✜ Update News Online ✜ AstraZeneca to cut more jobs
From our November 8th, 2011 Broadcast Update News is City of Wilmington's source for local news and information. ----------------------------------------------- British drug maker AstraZeneca, which has its North American headquarters in North Wilmington, has announced another round of layoffs. The company plans to cut 400 jobs by early next year. AstraZeneca had previously cut 550 jobs in March of 2010. In a statement of the drug giant said the move is "part of the company strategy to operate its business more effectively and efficiently to best serve patients in the United States". Adding that the changes "will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generic medicines". AstraZeneca is looking to combat a loss of revenue, as patents on the drugs Crestor, Nexium, and Seroquel are about to expire. The layoffs in Delaware will be mostly from positions in human resources, finance and marketing. ------------------------------- Update News airs at 7am, 12 noon, and 10pm EVERYDAY on WITN Channel 22 in the City of Wilmington Delaware. ✜ Update News ✜ Paul Colsey [Producer/Director] Paul Kennard [Anchor/Producer]
Views: 804 WITN Channel 22
Resistance Movement: Drugs, bugs and the fight against über-germs - Longwood Seminar
Streamed live on Mar 28, 2017 With many bacteria becoming impervious to drugs, new approaches are needed to combat the rise of antibiotic resistance. In this seminar, Harvard scientists and clinicians will discuss the history of drug resistance, how bacteria become able to shrug off the medications we use to treat disease, and ways to address the crisis. Like Harvard Medical School on Facebook: https://goo.gl/4dwXyZ Follow on Twitter: https://goo.gl/GbrmQM Follow on Instagram: https://goo.gl/s1w4up Follow on LinkedIn: https://goo.gl/04vRgY Website: https://hms.harvard.edu/
Pfizer's strategy to delay Lipitor market share loss the generic atorvastatin
Pharmacist Cynthia Jackevicius of Western University of Health Sciences discusses her New England Journal of Medicine article on the cost savings to the American healthcare system from cheaper generic Lipitor and the strategy Pfizer is using to delay the market share shift to generics
Biocon Posts Healthy Numbers In Q4
Biocon's Q4 revenue growth was above expectations. The company clocked a growth rate of 17% led primarily by its contract research division -Syngene. Ekta Batra and Nisha Poddar report on the growth triggers for Biocon.
Views: 125 CNBC-TV18
EVA PHARMA "English Ad"
VISION By 2016: Become the biggest Egyptian pharmaceutical company and one of the top three in the MENA region. A multinational company with sales out of Egypt more than inside Egypt. Secure the health of 80 Million Egyptians, 400 million MENA citizens and 1 billion Africans
Views: 728 IBRAM MAGDY
Watson Pharmaceuticals Acquires Specifar For $562 Million
Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today it has acquired the privately held Specifar Pharmaceuticals S.A., a multinational generic pharmaceutical developer, manufacturer and marketer, for $562 million in cash and certain contingent consideration. The transaction also gives Watson a strong branded-generic commercial presence in the $8.4 billion Greek pharmaceutical market. Specifar's former owners could also receive additional consideration based upon future profits of Esomeprazole tablets during its first five years of sales, up to a maximum of about $56 million. Watson anticipates that the transaction will be immediately accretive to 2011 non-GAAP earnings. Specifar, which had revenues of approximately $119 million in 2010, operates two core businesses. The Company is a third-party product developer, with approximately 400 marketing authorizations licensed to third parties for sale in 36 countries, mostly in Europe. Specifar has eight products currently on file in the EU and additional products in development. The Company's international development business accounts for over 70% of total revenues. Paul Bisaro, Watson's President and CEO said, "We are very pleased that Specifar has become part of our global organization. We look forward to working with the management team to continue Specifar's growth and to expanding the opportunities for success within Watson."
Views: 771 FinancialNewsOnline
Today's Alternative News Channel - PHARMAGEDDON Big Pharma is America’s new mafia whose chemical warfare on humanity dwarfs the number of victims killed by all the world wars and acts of terrorism combined. While drug companies profit billions, people are dying by the millions. It makes you wonder if Pharmageddon is upon us with the next set of mandatory vaccinations planned by the Center for Disease Control (CDC) for the profit of drug companies. THERE IS A WAR RAGING FOR CONTROL OF YOUR BLOODSTREAM AND IT IS LED BY THE FDA, CDC, WHO, AND BIG PHARMA, AND IT LOOKS AS IF THEY ARE WINNING. Over 70% of Americans are on some form of pharmaceutical drug that often brings negative side-effects, including death. Iatrogenic death, or “death by doctor”, is considered the third leading cause of death in America, conservatively speaking. Some experts interpret the data to read iatrogenic death as the number one cause of death, and they have a great deal of evidence to back up the claim. These statistics suggest that we should change the name “health industry” to “illness industry.” Conservative estimates suggest that America spends about 20% of the Gross Domestic Product (GDP) on health costs, about $3.35 trillion this year, which works out to $10,345 for every man, woman and child. Hospitals account for about 32%, doctors for 20%, and prescription drugs 10%. Spending on prescription drugs in the U.S. rose to a record $425 billion in 2016. The vaccine business alone is currently a $30 billion per year industry and the World Health Organization has urged increased vaccines, projecting that it will become a $100 billion per year industry by 2025. It is evident that the federal CDC and their business partners need the public to “be okay” with the current 69 doses of recommended childhood vaccines, plus adherence for an additional 100 plus doses of vaccines recommended by the CDC’s new adult schedule. Folks, they want us to inject our families with the additional 271 vaccines that are in the development pipeline. But nowhere on the CDC’s web site can you find a disclosure that the agency is a profit partner with the vaccine makers for whom it is supposed to be providing federal safety oversight. There are 57 granted U.S. patents with the CDC listed as an assignee. Some of the vaccine patents include: Flu, Rotavirus, Hepatitis A, HIV, Anthrax, Rabies, Dengue fever, West Nile virus, Group A Strep, Pneumococcal disease, Meningococcal disease, RSV, Gastroenteritis, Japanese encephalitis, SARS, Rift Valley Fever, and chlamydophila pneumoniae, flavivirus infection, human rhinovirus, adjuvants, Canarypox virus, Fowlpox virus, Sealpox virus, and dog flu. Source: http://stateofthenation2012.com/?p=69790 See our playlist for additional information: POLITICS: https://www.youtube.com/playlist?list=PL3vNhMt4w_SI_yFQvfelBTllKUpszHtGt HEALTH NEWS: https://www.youtube.com/playlist?list=PL3vNhMt4w_SKrC2qOLET6ydlt3Lvx29i_ TECH AND SCIENCE STUFF: https://www.youtube.com/playlist?list=PL3vNhMt4w_SKhC5M0NKTePMwwwezcPFjL Today's Alternative News https://www.youtube.com/channel/UCV6WBPEdQPZAVddWfmk1-Dg https://youtu.be/xzM7Y9JcEEs junenela54
CNBC-TV18 Exclusive: `4,500 Cr Sahara Property Auction Process Begins
In what is easily one of the biggest pan India land sales, SEBI appointed SBI Caps and HDFC Realty have started the process of selling Sahara Group's properties to mobilise money to repay investors. CNBC-TV18's Ritu Singh brings us all the details here.
Views: 63 CNBC-TV18
Orange Game Download demo
This video is an example of how Podo is helping a wireless provider generate new in-store revenue streams by inviting shoppers to download video games directly to their phones while visiting the retail location.
Views: 63 PODOTechnology
MUPS Technology: SQUARE PHARMA launches for the 1st time in Bangladesh
Corporate Website: http://www.squarepharma.com.bd/index.php facebook: https://www.facebook.com/SquarePharmaLtd/
Super Bowl Celebration...Weatherby Healthcare Style
Just some friendly competition at our office for the Super Bowl XLVII! We work hard to place the best providers in locum tenens and permanent positions, but we also play hard!
Introduction to Medicare Part D - Part D Event Cost Information
This presentation reviews the "cost" variables found in the Part D Event data. Researchers can determine the "point of sale" cost to the beneficiary. Other variables reviewed in this presentation include the gross drug cost, the patient pay amount, the low income subsidy amount, the other true out-of-pocket amount, patient liability reduction amount, and the covered and non-covered plan paid amounts.
Views: 256 ResDAC